Corcept Therapeutics Inc. diskutieren
Corcept Therapeutics Inc.
WKN: 529882 / Symbol: CORT / Name: Corcept / Aktie / Pharmazeutika / Small Cap /
21,87 €
1,93 %
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $33.00 to $32.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at HC Wainwright from $32.00 to $34.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at Truist Financial Co. from a "hold" rating to a "buy" rating. They now have a $38.00 price target on the stock, up previously from $29.00.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target lowered by analysts at HC Wainwright from $34.00 to $28.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its price target raised by analysts at Truist Financial Co. from $36.00 to $42.00. They now have a "buy" rating on the stock.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for CORT provided by MarketBeat
Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Ratings data for CORT provided by MarketBeat
Neueste Beiträge
DA_Davidson in Douglas Dynamics Inc. diskutieren